[产业发展] The Price of Global Health Drug Pricing Strategies to Balance Patient Access and [推广有奖]

0关注
324
粉丝

已卖：112955份资源

泰斗

25%

还不是VIP/贵宾

TA的文库 其他...

大家开心文库

威望: 9 级
论坛币: 1035857 个
通用积分: 951.6876
学术水平: 3617 点
热心指数: 3599 点
信用等级: 3043 点
经验: 610209 点
帖子: 1860
精华: 204
在线时间: 2058 小时
注册时间: 2013-10-3
最后登录: 2025-12-29

楼主

大家开心 发表于 2015-8-3 11:03:58 |AI写论文

是否 +2 论坛币

k人参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群

赵安豆老师微信：zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

立即领取

感谢您参与论坛问题回答

经管之家送您两个论坛币！

+2 论坛币

Public debate continues to intensify in the US and many other countries due to the rising cost of new biotechnology drug treatments and concern over patient ability to (co-)pay and adhere to these expensive treatments. Demand for new effective medical and drug treatments meanwhile continues to rise as unhealthy lifestyles further cause increases in diabetes and cardiovascular disease, thus further adding to the problem.Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries that produce products that kill? Ed Schoonveld explains how pharmaceutical prices are determined in a complex global player environment and what factors influence the process. His insights will help a wide range of audiences - from healthcare industry professionals to policy makers and the broader public - to gain a better understanding of this highly complex and emotionally charged field.The Price of Global Health is the first book of its kind: an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much-needed and invaluable resource for anybody interested or involved in, or affected by the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs.The second edition contains a large amount of new content, including four new chapters, many updates, new examples and all new illustrations. Furthermore, the country system descriptions have been updated to reflect Obamacare, AMNOG in Germany and many other changes.